keyword
MENU ▼
Read by QxMD icon Read
search

Pemetrexed

keyword
https://www.readbyqxmd.com/read/28730963/increased-expression-of-ire1%C3%AE-associates-with-the-resistant-mechanism-of-osimertinib-azd9291-resistant-non-small-cell-lung-cancer-hcc827-osir-cells
#1
Zheng-Hai Tang, Min-Xia Su, Xia Guo, Xiao-Ming Jiang, Lin Jia, Xiuping Chen, Jin-Jian Lu
BACKGROUND: Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of non-small cell lung cancer (NSCLC) patients. OBJECTIVE: Establishment of the OSI-resistant HCC827/OSIR cell line and study of its resistant mechanism. METHOD: The anti-proliferative effect was studied through MTT and colony formation assays. The protein expression was detected by Western blot assay...
July 19, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28726660/pemetrexed-induced-pseudocellulitis-a-rare-cutaneous-adverse-reaction-to-multi-targeted-antifolate-therapy
#2
U Hansel G Zschuppe E Tchernev G Wollina
Pemetrexed is a multi-targeted folate antagonists approved for non-small cell lung cancer and other malignancies. Adverse cutaneous reactions have been reported in up to 1/3 of patients treated. A rare cutaneous adverse reaction is pseudocellulitis. We report about a 62-year-old male patient treated with a combination of cisplatin and pemetrexed for non-small cell lung cancer stage IV who developed about 4 months after initiation of treatment painful, non-febrile erythematous lesions on feet and lower legs...
June 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28721071/adverse-renal-effects-of-anaplastic-lymphoma-kinase-inhibitors-and-the-response-to-alectinib-of-an-alk-lung-cancer-patient-with-renal-dysfunction
#3
Midori Shimada, Minoru Fukuda, Masaaki Fukuda, Takeshi Kitazaki, Kohji Hashiguchi, Takaya Ikeda, Hiroyuki Yamaguchi, Katsumi Nakatomi, Kazuto Ashizawa, Hiroshi Mukae
A 62-year-old female patient with renal dysfunction and pulmonary adenocarcinoma developed postoperative recurrence and received carboplatin/pemetrexed and maintenance pemetrexed. As an anaplastic lymphoma kinase (ALK) gene translocation was identified, the therapy was changed to crizotinib. However, the patient's blood creatinine level increased, and her physical status worsened. Alectinib also induced exacerbation of renal dysfunction but was controlled by dose reduction of 140 mg twice daily for 2 weeks treatment and 2 weeks break were repeated, and exhibited a partial response for 16 months...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28719077/metformin-synergistic-pemetrexed-suppresses-non-small-cell-lung-cancer-cell-proliferation-and-invasion-in-vitro
#4
Yan Zhang, Xiuli Feng, Tao Li, Erpan Yi, Yu Li
The aim of this study was to investigate whether metformin in combination with pemetrexed has an effect on the treatment of non-small-cell lung cancer (NSCLC) models and to explore the related molecular mechanism. The half maximal inhibitory concentration (IC50) and combination index (CI) of metformin and pemetrexed were detected by the CCK8 assay to assess the antiproliferative and therapeutic effects of the two-drug combination. Flow cytometry (FCM) and invasion assays were used to estimate the variation in apoptosis rate and invasion ability of the differently treated NSCLC cell lines...
July 18, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28710746/osimertinib-a-review-in-t790m-positive-advanced-non-small-cell-lung-cancer
#5
REVIEW
Yvette N Lamb, Lesley J Scott
Osimertinib (Tagrisso™) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. Osimertinib has been approved in numerous countries for use in patients with T790M-positive advanced NSCLC. In the pivotal, international AURA3 trial in patients with T790M-positive advanced NSCLC who had disease progression after EGFR TKI therapy, osimertinib treatment significantly prolonged progression-free survival (PFS; primary endpoint) compared with platinum-pemetrexed therapy at the time of the primary analysis...
July 14, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28709909/pemetrexed-conjugated-with-gold-nanoparticles-synthesis-characterization-and-a-study-of-noncovalent-interactions
#6
Elżbieta U Stolarczyk, Krzysztof Stolarczyk, Marta Łaszcz, Marek Kubiszewski, Andrzej Leś, Olga Michalak
Gold nanoparticles (AuNPs) have been widely used as nanocarriers in drug delivery application. However, the binding mechanism between AuNPs and drug bases still remains a puzzle. Our study included: (i) optimization of three synthesis of the AuNPs-pemetrexed (PE) nanocomposites formation which was monitored by UV-Vis spectroscopy, (ii) identification of PE in gold nanocomposites and mechanism of PE interaction with gold nanoparticles by electrochemistry, NMR and Raman measurements, (iii) characterization of the three nanocomposites by TEM, DSL, ESL, zeta potential, XRPD and TGA analysis...
July 11, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28700347/astrocyte-elevated-gene-1-confers-resistance-to-pemetrexed-in-non-small-cell-lung-cancer-by-upregulating-thymidylate-synthase-expression
#7
Chung-Yu Chen, Ying-Yin Chen, Jeremy J W Chen, Kuan-Yu Chen, Chao-Chi Ho, Jin-Yuan Shih, Yih-Leong Chang, Chong-Jen Yu, Pan-Chyr Yang
Previous studies have suggested that astrocyte-elevated gene-1 (AEG-1) contributes to the mechanisms of resistance to various chemotherapeutics. In this study, we investigated whether AEG-1 expression level correlated with that of thymidylate synthase (TS), as higher TS expression is known to be associated with the resistance to pemetrexed chemotherapy in patients with advanced lung adenocarcinoma. Using pemetrexed-resistant lung adenocarcinoma PC-9 cell line, we demonstrated that transfection of AEG-1 siRNA lowered TS expression and decreased pemetrexed IC50 value...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28697647/antimetabolites-in-the-treatment-of-advanced-pleural-mesothelioma-a-network-meta-analysis-of-randomized-clinical-trials
#8
Davide Tassinari, Chiara Cherubini, Emiliano Tamburini, Fabrizio Drudi, Maximilian Papi, Manuela Fantini, Luigi Lazzari-Agli, Sergio Sartori
An indirect comparison of cisplatin-pemetrexed (CP) and cisplatin-raltitrexed (CR) was performed. The Odds Ratios of 10, 15 and 20 month survival rate and response rate were assumed as indexes of efficacy; the Odds Ratio of grade III-IV side effects, and the absolute risk of overall, hematologic and non-hematologic toxicity, were assumed as indexes of safety. The outcomes of 352 patients were analysed. The Odds Ratios and 95% Confidence Interval (95% CI) of 10, 15 and 20 months survival rate and response rate were 1...
July 11, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/28695808/impact-of-lymphocyte-subsets-on-chemotherapy-efficacy-and-long-term-survival-of-patients-with-advanced-non-small-cell-lung-cancer
#9
Zhimin Wei, Weiqiang Zhang, Feng Gao, Yunbo Wu, Guoqing Zhang, Zhefeng Liu, Shunchang Jiao
Objective To analyze the impact of lymphocyte subsets on chemotherapy efficacy and long-term survival of patients with advanced non-small cell lung cancer(NSCLC).Methods Totally 125 NSCLC patients who had received first-line chemotherapy including paclitaxel and pemetrexed with/without platinum were enrolled in this study.Lymphocytes from peripheral blood were collected before and after two cycles of first-line chemotherapy.Flow cytometry was performed to determine the expressions of 21 fluorescence-labeled lymphocyte subsets...
June 20, 2017: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
https://www.readbyqxmd.com/read/28690011/lume-meso-design-and-rationale-of-the-phase-iii-part-of-a-placebo-controlled-study-of-nintedanib-and-pemetrexed-cisplatin-followed-by-maintenance-nintedanib-in-patients-with-unresectable-malignant-pleural-mesothelioma
#10
Giorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, Martin Reck, Anne S Tsao, Jan van Meerbeeck, Nicholas J Vogelzang, Takashi Nakano, Ute von Wangenheim, Derek Velema, Nassim Morsli, Sanjay Popat
Malignant pleural mesothelioma (MPM) is a rare but aggressive disease: median survival is 6 to 9 months if untreated. Standard first-line treatment for patients with unresectable MPM is cisplatin/pemetrexed, with a median overall survival (OS) of approximately 1 year. Improvements in first-line treatment options are needed. With the benefit of combining bevacizumab with standard therapy shown in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS), vascular endothelial growth factor (VEGF) pathway inhibition has gained renewed interest as a treatment approach...
March 22, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28685068/protein-and-mrna-expression-of-folic-acid-associated-enzymes-as-biomarkers-for-the-cytotoxicity-of-the-thymidylate-synthase-targeted-drugs-pemetrexed-and-s-1-in-non-small-cell-lung-cancer
#11
Madoka Kimura, Fumio Imamura, Takako Inoue, Kazumi Nishino, Junji Uchida, Toru Kumagai, Jiro Okami, Masahiko Higasiyama, Shingo Kamoshida
The thymidylate synthase (TS)-targeted drugs, pemetrexed and S-1, exert an important role in advanced non-small cell lung cancer (NSCLC) treatment; folic acid-associated enzymes are expected to behave as biomarkers, although their role has yet to be fully elucidated. In the present study, a single-institutional prospective analysis, in which the mRNA and protein expression levels of five folic acid-associated enzymes were evaluated with surgical specimens of NSCLC, was performed. Drug sensitivity was evaluated using a collagen gel droplet-embedded culture drug sensitivity test (CD-DST) in vitro...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28681936/toxicity-of-chemotherapy-regimens-in-advanced-and-metastatic-pancreatic-cancer-therapy-a-network-meta-analysis
#12
Xiao-Fang Wang, Wen-Feng Huang, Jian Nie, Yong Zhou, Ding-Wu Tan, Ji-Hao Jiang
This network meta-analysis is adopted in order to compare the toxicity of different chemotherapy regimens in the treatment of advanced/metastatic pancreatic cancer (PC). Randomized controlled trials (RCTs) about different chemotherapy regimens for advanced/metastatic PC were included in this network meta-analysis using Cochrane Library and PubMed electronic databases. The network meta-analysis was performed to combine direct and indirect evidence in order to calculate the odd ratios (OR) and draw a surface under the cumulative ranking (SUCRA) curve...
July 6, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28676211/cost-effectiveness-analysis-of-additional-bevacizumab-to-pemetrexed-plus-cisplatin-for-malignant-pleural-mesothelioma-based-on-the-maps-trial
#13
Mei Zhan, Hanrui Zheng, Ting Xu, Yu Yang, Qiu Li
PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy, and pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the cost-effectiveness of the addition of bevacizumab to PC (with maintenance bevacizumab) for unresectable MPM based on a phase III trial that showed a survival benefit compared with chemotherapy alone. METHODS: To estimate the incremental cost-effectiveness ratio (ICER) of the incorporation of bevacizumab, a Markov model based on the MAPS trial, including the disease states of progression-free survival, progressive disease and death, was used...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28673332/a-multicenter-survey-of-first-line-treatment-patterns-and-gene-aberration-test-status-of-patients-with-unresectable-stage-iiib-iv-nonsquamous-non-small-cell-lung-cancer-in-china-ctong-1506
#14
Qing Zhou, Yong Song, Xin Zhang, Gong-Yan Chen, Dian-Sheng Zhong, Zhuang Yu, Ping Yu, Yi-Ping Zhang, Jian-Hua Chen, Yi Hu, Guo-Sheng Feng, Xia Song, Qiang Shi, Lu Lu Yang, Ping Hai Zhang, Yi-Long Wu
BACKGROUND: In recent years, systemic chemotherapy and molecular targeted therapy have become standard first-line treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). The objective of this survey was to investigate first-line anticancer treatment patterns and gene aberration test status of patients with advanced nonsquamous NSCLC in China. METHODS: Patients included in this study had unresectable Stage IIIB/IV nonsquamous NSCLC and were admitted during August 2015 to March 2016 into one of 12 tertiary hospitals throughout China for first-line anticancer treatment...
July 3, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28668866/histology-based-combination-induction-chemotherapy-for-elderly-patients-with-clinical-stage-iii-non-small-cell-lung-cancer
#15
Giuseppe L Banna, Hector Josè Soto Parra, Marine Castaing, Maria Vittoria Dieci, Giuseppe Anile, Maurizio Nicolosi, Salvatore Strano, Francesco Marletta, Valentina Guarneri, Pierfranco Conte, Rohit Lal
AIM: To explore the feasibility and activity of a histology-based induction combination chemotherapy for elderly patients with clinical stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients aged ≥70 years with stage IIIA and IIIB lung squamous cell carcinoma (SCC) or adenocarcinoma were treated with three cycles of carboplatin and gemcitabine or pemetrexed, respectively, followed by definitive radiotherapy or surgery. The primary endpoint was the overall response rate (ORR) following induction...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28668204/randomized-phase-iii-study-of-cisplatin-with-pemetrexed-and-cisplatin-with-vinorelbine-for-completely-resected-nonsquamous-non-small-cell-lung-cancer-the-jipang-study-protocol
#16
Nobuyuki Yamamoto, Hirotsugu Kenmotsu, Takeharu Yamanaka, Shinichiro Nakamura, Masahiro Tsuboi
This trial report describes the background and design for the Japan Intergroup Trial of Pemetrexed Adjuvant Chemotherapy for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer (JIPANG) study (University Hospital Medical Information Network database: UMIN000006737). Various randomized trials have shown the efficacy of postoperative adjuvant chemotherapy regimens that include cisplatin for resected non-small-cell lung cancer (NSCLC), but the optimal regimen is not known. The JIPANG study is a randomized study comparing cisplatin (75 mg/m(2), day 1) and pemetrexed (500 mg/m(2), day 1) with cisplatin (80 mg/m(2), day 1) and vinorelbine (25 mg/m(2), days 1 and 8) for nonsquamous NSCLC as postoperative adjuvant chemotherapy...
June 8, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28667792/phase-i-study-of-salazosulfapyridine-in-combination-with-cisplatin-and-pemetrexed-for-advanced-non-small-cell-lung-cancer
#17
Kohei Otsubo, Kaname Nosaki, Chiyo K Imamura, Hiroaki Ogata, Akitaka Fujita, Shinya Sakata, Fumihiko Hirai, Gouji Toyokawa, Eiji Iwama, Taishi Harada, Takashi Seto, Mitsuhiro Takenoyama, Takeshi Ozeki, Taisei Mushiroda, Mieko Inada, Junji Kishimoto, Kenji Tsuchihashi, Kentaro Suina, Osamu Nagano, Hideyuki Saya, Yoichi Nakanishi, Isamu Okamoto
Splice variant isoforms of CD44 (CD44v) are a marker of cancer stem cells (CSCs) in solid tumors. They stabilize the xCT subunit of the transporter system xc(-) and thereby promote synthesis of the antioxidant glutathione. Salazosulfapyridine (SASP) is an inhibitor of xCT and suppresses the proliferation of CD44v-positive cancer cells. Chemotherapy-naïve patients with advanced nonsquamous non-small cell lung cancer were enrolled in a dose-escalation study (standard 3 + 3 design) of SASP in combination with cisplatin and pemetrexed...
July 1, 2017: Cancer Science
https://www.readbyqxmd.com/read/28660548/chemotherapy-induced-cardiomyopathy-caused-by-pemetrexed
#18
Takuya Oyakawa, Kei Iida, Masatoshi Kusuhara, Hirotsugu Kenmotsu, Takashi Sugino
Chemotherapy-related cardiac toxicity is a rare but serious adverse event in patients with cancer. Thus far, no case of serious cardiac toxicity of pemetrexed has been reported. We describe the case of a patient with advanced lung cancer and cardiomyopathy due to pemetrexed. A 59-year-old woman visited our hospital, and we found abnormal findings on a chest radiograph. She was diagnosed as having stage IV lung adenocarcinoma. Chemotherapy with cisplatin and pemetrexed every 3 weeks was initiated. After four cycles of chemotherapy, maintenance chemotherapy with pemetrexed was administered every 3 weeks...
June 28, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28644837/real-world-first-line-treatment-and-overall-survival-in-non-small-cell-lung-cancer-without-known-egfr-mutations-or-alk-rearrangements-in-us-community-oncology-setting
#19
Amy P Abernethy, Ashwini Arunachalam, Thomas Burke, Caroline McKay, Xiting Cao, Rachael Sorg, David P Carbone
PURPOSE: To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations. METHODS: Using a nationally representative electronic health record data from the Flatiron dataset which included 162 practices from different regions in US, we identified patients (≥18 years old) newly diagnosed with stage IV NSCLC initiating first-line anticancer therapy (November 2012- January 2015, with follow-up through July 2015)...
2017: PloS One
https://www.readbyqxmd.com/read/28633504/a-phase-ii-study-of-palonosetron-aprepitant-dexamethasone-and-olanzapine-for-the-prevention-of-cisplatin-based-chemotherapy-induced-nausea-and-vomiting-in-patients-with-thoracic-malignancy
#20
Kazuhisa Nakashima, Haruyasu Murakami, Kouichi Yokoyama, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Fumie Nishiyama, Mami Kikugawa, Masayo Kaneko, Yumiko Iwamoto, Satomi Koizumi, Keita Mori, Takeshi Isobe, Toshiaki Takahashi
Background: The three-drug combination of a 5-hydroxytryptamine type 3 receptor antagonist, a neurokinin 1 receptor antagonist and dexamethasone is recommended for patients receiving highly emetogenic chemotherapy. However, standard antiemetic therapy is not completely effective in all patients. Methods: We conducted an open-label, single-center, single-arm Phase II study to evaluate the efficacy of olanzapine in combination with standard antiemetic therapy in preventing chemotherapy-induced nausea and vomiting in patients with thoracic malignancy receiving their first cycle of cisplatin-based chemotherapy...
June 17, 2017: Japanese Journal of Clinical Oncology
keyword
keyword
8879
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"